Embecta, a diabetes care technology company, announced that it has entered into a definitive agreement to acquire Owen Mumford Holdings Limited, a UK-based medical device innovator, for up to £150 million. The deal includes an upfront cash payment of £100 million at closing, along with up to £50 million in performance-based payments tied to net sales of the Aidaptus auto-injector platform over the three years following closing.
The transaction, unanimously approved by Embecta’s board of directors, is expected to close in the company’s fiscal third quarter of 2026, subject to regulatory approvals and customary closing conditions.
Owen Mumford is known for its expertise in drug delivery platforms and medical device technologies, with a portfolio spanning autoinjectors, point-of-care diagnostics, self-injection devices, and pelvic health solutions. The company generated approximately £69.4 million in revenue in fiscal year 2025, with around 80% of its sales coming from the UK and the United States.
The acquisition is designed to accelerate Embecta’s transformation into a broader medical supplies company while expanding its reach into drug delivery devices supporting therapies across multiple areas, including obesity, autoimmune diseases, and anaphylaxis. Owen Mumford’s Aidaptus auto-injector platform is expected to play a central role, offering a streamlined manufacturing process and scalable design intended to support pharmaceutical partners.
Embecta also expects to leverage its global commercial infrastructure, which spans more than 100 countries, to expand Owen Mumford’s geographic reach and scale its product portfolio. The combined capabilities are anticipated to enhance manufacturing efficiencies by integrating Owen Mumford’s device design and assembly expertise with Embecta’s high-volume production capabilities.
From a financial perspective, Embecta expects the acquisition to contribute to revenue growth beginning in fiscal year 2027. The deal is projected to be dilutive to adjusted net income in fiscal 2027, neutral in fiscal 2028, and accretive thereafter. The company also anticipates generating a high-single-digit return on invested capital by the fourth year following closing, with increasing contributions over time.
To finance the transaction, Embecta plans to utilize borrowings under its revolving credit facility while maintaining a long-term commitment to reducing debt and strengthening financial flexibility.
The company said it will provide additional details about the acquisition during its fiscal second quarter 2026 earnings call scheduled for May 5, 2026.
KEY QUOTES
“We are extremely pleased to announce this agreement to acquire Owen Mumford, a company that has earned a global reputation for innovation, quality and patient-centered design. This acquisition is expected to sustainably improve embecta’s revenue growth trajectory and will accelerate our strategic transformation into a broad-based medical supplies company which provides drug delivery platforms to pharmaceutical companies and serves chronic care patients in the obesity, diabetes, autoimmune diseases and anaphylaxis markets.”
Devdatt (Dev) Kurdikar, Chairman, President And CEO Of Embecta Corp.
“Owen Mumford has a 70-year track-record of developing innovative solutions with long-term growth potential. With our complementary portfolios and manufacturing expertise, and by leveraging embecta’s commercial scale, we will continue to drive innovation that improves the quality of life for people living with chronic conditions and other healthcare needs while creating new opportunities for our valued customers and the Owen Mumford team.”
Gavin Jones, Managing Director Of Owen Mumford Holdings Limited
